Pharmacokinetics and Pharmacodynamics of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis

@article{Sun2016PharmacokineticsAP,
  title={Pharmacokinetics and Pharmacodynamics of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis},
  author={Haiying Sun and Linh M. Van and David Floch and Xuemin Jiang and Ulf R. Klein and Ken Abrams and Gangadhar Sunkara},
  journal={The Journal of Clinical Pharmacology},
  year={2016},
  volume={56}
}
The characterization of the pharmacokinetic (PK) and pharmacodynamic (PD) properties in pediatric patients is essential in supporting the recommended dosage of canakinumab in the relevant population. Here the PK and PD properties of canakinumab—a monoclonal antibody—in pediatric patients with systemic juvenile idiopathic arthritis (SJIA) are presented. Blood samples were obtained from 4 phase 2/3 clinical studies in patients with SJIA. Canakinumab PK properties and total interleukin (IL)‐1… Expand
Development and Role in Therapy of Canakinumab in Adult-Onset Still’s Disease
TLDR
The structural and biochemical data describing the molecular interactions between Canakinumab and its target antigen are summarized and the safety, efficacy and tolerability of this drug for the treatment of AOSD are reviewed. Expand
Efficacy and safety of canakinumab in patients with Still's disease: exposure-response analysis of pooled systemic juvenile idiopathic arthritis data by age groups.
TLDR
Pooled analyses from SJIA studies indicate that older adolescents and young adults SJIA patients show similar efficacy, safety, and exposure-response relationship on a weight-based dosing regimen as observed in children and adolescent SJIA Patients. Expand
Dosage Considerations for Canakinumab in Children With Periodic Fever Syndromes
TLDR
The pharmacokinetic (PK), efficacy, safety, and exposure‐response relationship of canakinumab is discussed and the rationale for dosage recommendation in children younger than 2 years of age with the three conditions of periodic fever syndromes is provided. Expand
Canakinumab for the treatment of adult-onset Still’s disease
TLDR
The available data for canakinumab indicate that this drug in AOSD patients is effective and well tolerated, and there is no unanimous consensus on how to treat with IL-1 inhibitors. Expand
Canakinumab injection for the treatment of active Still’s disease, including adult-onset Still’s disease
ABSTRACT Introduction Still’s disease is a systemic, non-monogenic autoinflammatory condition affecting both children and adolescents (systemic juvenile idiopathic arthritis, sJIA) and adultsExpand
Pediatric Dose Selection for Therapeutic Proteins
TLDR
Translation of the quantitative characterization of the pediatric pharmacokinetics of therapeutic proteins into dosing regimens for the drug label requires compromising between precision dosing and clinical practicability, with tiered dosing algorithms based on size or age strata being the currently most frequently applied methodology. Expand
Canakinumab for the treatment of familial Mediterranean fever
TLDR
The accumulating data indicates that anti IL-1 drugs are effective in treating colchicine resistant FMF cases and improving their quality of life, which highlights its importance as the alternative treatment in FMF. Expand
Canakinumab in patients with systemic juvenile idiopathic arthritis and active systemic features: results from the 5-year long-term extension of the phase III pivotal trials
TLDR
Response to canakinumab treatment was sustained and associated with substantial glucocorticoid dose reduction or discontinuation and a relatively low retention-on-treatment rate, and no new safety findings were observed. Expand
Pharmacokinetic Variability of Therapeutic Antibodies in Humans: A Comprehensive Review of Population Pharmacokinetic Modeling Publications
TLDR
A quantitative overview of the occurrence of assessment and detection of the main covariates associated with monoclonal antibody pharmacokinetics is proposed by comprehensively examining all population pharmacokinetic studies of monoconal antibodies in humans. Expand
Influence of Antigen Mass on the Pharmacokinetics of Therapeutic Antibodies in Humans
TLDR
This review focuses on the influence of antigen mass on the pharmacokinetics of therapeutic antibodies quantified by pharmacokinetic modelling in humans, which led to non-linear elimination decay in 50 publications. Expand
...
1
2
3
...

References

SHOWING 1-10 OF 37 REFERENCES
Pharmacokinetic and pharmacodynamic properties of canakinumab in patients with gouty arthritis
TLDR
Canakinumab treatment provided rapid, sustained decreases in C‐reactive protein and serum amyloid A, provided superior pain relief to triamcinolone acetonide, and increased time to first recurrent attack in gouty arthritis patients. Expand
Pharmacokinetic and Pharmacodynamic Properties of Canakinumab, a Human Anti-Interleukin-1β Monoclonal Antibody
TLDR
Analysis of the pharmacokinetic and pharmacodynamic data from the canakinumab clinical development programme is described, describing results from the recently approved indication for the treatment of cryopyrin-associated periodic syndromes under the trade name ILARIS®, as well as diseases such as rheumatoid arthritis, asthma and psoriasis. Expand
Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis
TLDR
The disposition of infliximab in patients with moderately to severely active ulcerative colitis, unlike in rheumatoid arthritis, was not affected by coadministration of immunomodulators and corticosteroids but was related to formation of antibodies to inflIXimab and, notably, to serum albumin levels. Expand
Use of canakinumab in the cryopyrin-associated periodic syndrome.
TLDR
Treatment with subcutaneous canakinumab once every 8 weeks was associated with a rapid remission of symptoms in most patients with CAPS and evaluated therapeutic responses using disease-activity scores and analysis of levels of C-reactive protein (CRP) and serum amyloid A protein (SAA). Expand
Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis.
TLDR
These two phase 3 studies show the efficacy and safety of canakinumab in systemic JIA with active systemic features, and among the 100 patients who underwent randomization in the withdrawal phase, the risk of flare was lower among patients who continued to receive canakinUMab than among those who were switched to placebo. Expand
A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features.
TLDR
Canakinumab has a promising preliminary safety and efficacy profile in this limited cohort of children with systemic juvenile idiopathic arthritis and active systemic features and further studies in a larger population ofChildren with systemic JIA are warranted. Expand
Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes
TLDR
Subcutaneous canakinumab 150 mg every 8 weeks was well tolerated and provided substantial disease control in children and adults across all CAPS phenotypes. Expand
Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study
TLDR
Single canakinumab doses ≥50 mg or four 4-weekly doses provided superior prophylaxis against flares compared with daily colchicine 0.5 mg at 16 weeks. Expand
Pediatric Dosing of Rituximab Revisited: Serum Concentrations in Opsoclonus-myoclonus Syndrome
TLDR
The results indicate that the degree of serum IgM depletion is a useful indicator for rituximab dose equivalency in children of different ages, and suggest that pediatric ritUXimab dosing should be based on body weight, not surface area. Expand
Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: Results of a multicenter, phase II, dose-ranging study.
TLDR
It is indicated that canakinumab 150 mg provides rapid and sustained pain relief in patients with acute gouty arthritis, and significantly reduces the risk of recurrent flares compared with triamcinolone acetonide. Expand
...
1
2
3
4
...